CN1191273C - 长效促胰岛肽 - Google Patents

长效促胰岛肽 Download PDF

Info

Publication number
CN1191273C
CN1191273C CNB008065489A CN00806548A CN1191273C CN 1191273 C CN1191273 C CN 1191273C CN B008065489 A CNB008065489 A CN B008065489A CN 00806548 A CN00806548 A CN 00806548A CN 1191273 C CN1191273 C CN 1191273C
Authority
CN
China
Prior art keywords
fmoc
seq
peptide
lys
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008065489A
Other languages
English (en)
Chinese (zh)
Other versions
CN1350548A (zh
Inventor
多米尼克·P·布里顿
伯努瓦·拉尔谢维克
阿朗·M·埃斯林
达伦·L·霍姆斯
阿努克·勒布朗
瑟奇·圣皮埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changshan Kaijiejian Biological Drug R & D Hebei Co ltd
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of CN1350548A publication Critical patent/CN1350548A/zh
Application granted granted Critical
Publication of CN1191273C publication Critical patent/CN1191273C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008065489A 1999-05-17 2000-05-17 长效促胰岛肽 Expired - Lifetime CN1191273C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17
US15978399P 1999-10-15 1999-10-15
US60/159,783 1999-10-15

Publications (2)

Publication Number Publication Date
CN1350548A CN1350548A (zh) 2002-05-22
CN1191273C true CN1191273C (zh) 2005-03-02

Family

ID=26832298

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008065489A Expired - Lifetime CN1191273C (zh) 1999-05-17 2000-05-17 长效促胰岛肽

Country Status (16)

Country Link
US (4) US6329336B1 (enExample)
EP (1) EP1180121B9 (enExample)
JP (5) JP4115671B2 (enExample)
CN (1) CN1191273C (enExample)
AT (1) ATE252601T1 (enExample)
AU (1) AU754770B2 (enExample)
BR (1) BR0010750A (enExample)
CA (2) CA2501421A1 (enExample)
DE (1) DE60006100T2 (enExample)
DK (1) DK1180121T3 (enExample)
EA (1) EA003922B1 (enExample)
ES (1) ES2209885T3 (enExample)
NO (1) NO20015584L (enExample)
PT (1) PT1180121E (enExample)
SI (1) SI1180121T1 (enExample)
WO (1) WO2000069911A1 (enExample)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
ATE252601T1 (de) * 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6447772B1 (en) * 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
SK288342B6 (en) * 2000-12-07 2016-03-01 Lilly Co Eli GLP-1 fusion proteins
CN101696240A (zh) 2001-02-02 2010-04-21 康久化学生物技术公司 长效生长激素释放因子衍生物
DE60226702D1 (de) * 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CA2448891A1 (en) 2001-05-31 2002-12-05 Conjuchem Inc. Long lasting fusion peptide inhibitors for hiv infection
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
AU2002323501C1 (en) * 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
JP2005514337A (ja) * 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20030166512A1 (en) * 2002-02-13 2003-09-04 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
NZ534125A (en) * 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
EP1575490A4 (en) * 2002-06-04 2007-08-08 Lilly Co Eli MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE60333306D1 (de) * 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
US7575750B2 (en) * 2002-09-24 2009-08-18 Frontiers Biotechnologies Col, Ltd. Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
KR101198346B1 (ko) * 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
CA2820537C (en) 2003-04-23 2015-10-20 Valeritas, Inc. Hydraulically actuated pump for fluid administration
CN1812983A (zh) 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
CA2526957C (en) * 2003-07-25 2011-07-12 Conjuchem Inc. Long lasting insulin derivatives and methods thereof
CN1964989B (zh) * 2003-07-25 2012-02-01 康久化学生物技术公司 长效胰岛素衍生物及其方法
AU2004265341A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
US20070275871A1 (en) * 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7214190B1 (en) 2003-09-09 2007-05-08 Kitchener Clark Wilson Apparatus and method for noninvasive monitoring of analytes in body fluids
KR20060109940A (ko) * 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2554458A1 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005095381A1 (en) * 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06012260A (es) * 2004-04-23 2006-12-15 Conjuchem Biotechnologies Inc Metodo para la purificacion de conjugados de albumina.
CN1318587C (zh) * 2004-04-30 2007-05-30 成都芝田生物工程有限公司 酰胺化Exendin－4多肽的重组制备方法
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
EP2330126B1 (en) 2004-10-07 2015-12-23 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US20080125361A1 (en) * 2004-11-12 2008-05-29 Novo Nordisk A/S Stable Formulations Of Peptides
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
US8716221B2 (en) * 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
CN102908351B (zh) * 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CN102675221A (zh) * 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK1987052T3 (da) * 2006-02-08 2011-08-15 Lonza Ag Syntese af glucagonlignende peptider
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
JP2009532117A (ja) 2006-03-30 2009-09-10 ヴァレリタス，エルエルシー マルチカートリッジ式流体投与装置
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR100886783B1 (ko) 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
AR061930A1 (es) 2006-07-18 2008-10-01 Centocor Inc Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
CL2007002634A1 (es) * 2006-09-13 2008-05-16 Smithkline Beecham Corp Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
DK2073810T3 (da) * 2006-09-13 2011-10-31 Takeda Pharmaceutical Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2205624B1 (en) * 2007-10-27 2016-09-07 Corden Pharma Colorado, Inc. Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
MX337038B (es) 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Co-antagonistas de receptor de glucagon/glp-1.
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
TW201012829A (en) * 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
MX2011004017A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de agonistas glp-1 y usos de los mismos.
BRPI0920881B1 (pt) 2008-10-17 2021-09-21 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
AU2010218139B2 (en) 2009-02-25 2012-11-01 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast Pichia pastoris
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
CA2766537A1 (en) * 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
KR101525473B1 (ko) * 2009-09-30 2015-06-03 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 및 그 사용
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
EP2504021A4 (en) 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
BR112012020882A2 (pt) 2010-02-24 2015-11-03 Merck Sharp & Dohme métodos para produzir uma glicoproteína heteróloga e para produzir uma composição de glicoproteína, célula hospedeira, composição de glicoproteína, e, uso da pichia pastoris recombinante.
CA2792663A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
PH12012502121A1 (en) 2010-04-27 2019-07-10 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
AU2011343190B2 (en) 2010-12-16 2016-12-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012122025A2 (en) * 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103189389B (zh) * 2011-09-03 2017-08-11 深圳市健元医药科技有限公司 新的glp‑ⅰ类似物及其制备方法和用途
CN102286092B (zh) * 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US9499587B2 (en) 2012-01-23 2016-11-22 University Of South Florida Gamma-AApeptides with potent and broad-spectrum antimicrobial activity
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013163162A1 (en) * 2012-04-24 2013-10-31 Amylin Pharmaceuticals, Llc Site-specific enzymatic modification of exendins and analogs thereof
US9289507B2 (en) 2012-05-17 2016-03-22 Extend Biosciences, Inc. Carriers for improved drug delivery
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
UA117103C2 (uk) 2012-07-23 2018-06-25 Зіленд Фарма А/С Сполука, яка має активність агоніста глюкагону
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6408998B2 (ja) 2012-12-21 2018-10-17 サノフイＳａｎｏｆｉ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニスト
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
HUE048687T2 (hu) 2013-02-18 2020-08-28 Vegenics Pty Ltd Ligandum kötõ molekulák és alkalmazásaik
CN105324397B (zh) 2013-03-14 2020-01-14 印第安纳大学研究及科技有限公司 胰岛素-肠促胰岛素缀合物
CN104592380A (zh) * 2013-03-15 2015-05-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
CN104650212A (zh) * 2013-03-15 2015-05-27 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
CN106029087A (zh) 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091964A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
BR112017012406A2 (pt) 2014-12-12 2018-07-31 Sanofi Aventis Deutschland formulação com relação fixa de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
LT3393496T (lt) 2015-12-23 2023-12-11 The Johns Hopkins University Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN108070030B (zh) * 2016-11-17 2023-06-23 江苏豪森药业集团有限公司 洛塞那肽及其类似物的制备方法
ES2979184T3 (es) 2016-12-09 2024-09-24 Zealand Pharma As Agonistas duales de glp-1/glp-2 acilados
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
US10905750B2 (en) 2017-11-10 2021-02-02 Donald J. Davidson GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
IL320142A (en) 2018-10-11 2025-06-01 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
CN109400695B (zh) 2018-10-31 2020-06-30 中南大学湘雅医院 一种多肽的修饰方法及应用
CN110183531A (zh) * 2019-05-17 2019-08-30 河北常山生化药业股份有限公司 一种艾本那肽前体的制备方法
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
US20230158165A1 (en) * 2020-03-27 2023-05-25 Epivax, Inc. Tregitope constructs useful in the prevention and treatment of type 1 diabetes
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN115819493A (zh) * 2022-11-16 2023-03-21 河北常山生化药业股份有限公司 一种多肽固相合成方法
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) * 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4423034A (en) * 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
CZ315594A3 (en) 1992-06-15 1995-07-12 Pfizer Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
NZ285501A (en) * 1994-04-26 1998-02-26 Childrens Medical Center Plasminogen analogs (angiostatin), endothelial inhibitors, assays and kits
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
CZ298612B6 (cs) 1995-12-13 2007-11-21 The Children's Medical Center Corporation Inhibitor proliferace endothelových bunek a jeho použití
WO1997025074A2 (en) 1996-01-12 1997-07-17 Redcell Canada, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
ID17252A (id) 1996-04-29 1997-12-11 Akzo Nobel Nv Proses pembuatan obyek yang terbuat dari selulosa
BR9708911A (pt) 1996-05-03 1999-08-03 Abbott Lab Composto fragmento de peptídeo processo par tratar uma doença em um paciente em necessidade de terapia antioangiogênese composição polinucleotídeo único ou de duplo-filamento isolado vetor e processo para produzir um fragmento de peptídeo de kringle 5 ou proteína de fusão de kringle 5 solúvel
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
TR199802789T2 (xx) 1996-06-05 1999-03-22 Boehringer Mannheim Gmbh Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
AU4351897A (en) * 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5864372A (en) * 1996-12-10 1999-01-26 United Microelectronics Corporation Apparatus for implementing a block matching algorithm for motion estimation in video image processing
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
EP1056474B1 (en) * 1997-11-07 2002-06-12 ConjuChem, Inc. Affinity markers for human serum albumin
ATE216402T1 (de) * 1997-11-07 2002-05-15 Conjuchem Inc Opioid-konjugate mit endogenen trägerproteinen
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
WO1999024015A1 (en) 1997-11-12 1999-05-20 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
BR9814189A (pt) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
EP1062229A1 (en) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
GB9815505D0 (en) 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
CA2343207A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Nasopharyngeal airway with reflectance pulse oximeter sensor
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) * 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
EP1153125B1 (en) 1999-02-10 2007-04-18 The Children's Medical Center Corporation Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
AU771755B2 (en) 1999-03-18 2004-04-01 Children's Medical Center Corporation Novel antiangiogenic peptides
WO2000061179A1 (en) 1999-04-14 2000-10-19 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
ATE226593T1 (de) * 1999-05-17 2002-11-15 Conjuchem Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
SI1105409T1 (sl) 1999-05-17 2006-06-30 Conjuchem Inc Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7144854B1 (en) * 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ATE252601T1 (de) * 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
CN101696240A (zh) * 2001-02-02 2010-04-21 康久化学生物技术公司 长效生长激素释放因子衍生物
DE60226702D1 (de) * 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
CA2448891A1 (en) * 2001-05-31 2002-12-05 Conjuchem Inc. Long lasting fusion peptide inhibitors for hiv infection
CA2526957C (en) * 2003-07-25 2011-07-12 Conjuchem Inc. Long lasting insulin derivatives and methods thereof
MXPA06012260A (es) * 2004-04-23 2006-12-15 Conjuchem Biotechnologies Inc Metodo para la purificacion de conjugados de albumina.
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
CA2363712A1 (en) 2000-11-23
DK1180121T3 (da) 2004-03-01
DE60006100D1 (de) 2003-11-27
US7741286B2 (en) 2010-06-22
EP1180121B1 (en) 2003-10-22
ES2209885T3 (es) 2004-07-01
AU4855500A (en) 2000-12-05
BR0010750A (pt) 2002-02-26
CA2501421A1 (en) 2000-11-23
JP4116016B2 (ja) 2008-07-09
PT1180121E (pt) 2004-03-31
US20060135428A1 (en) 2006-06-22
US20110071082A1 (en) 2011-03-24
EP1180121A1 (en) 2002-02-20
CN1350548A (zh) 2002-05-22
CA2363712C (en) 2011-05-10
EP1180121B9 (en) 2004-09-08
DE60006100T2 (de) 2004-07-01
JP2003527312A (ja) 2003-09-16
SI1180121T1 (en) 2004-04-30
JP2009001583A (ja) 2009-01-08
EA003922B1 (ru) 2003-10-30
US6329336B1 (en) 2001-12-11
NO20015584L (no) 2002-01-03
NO20015584D0 (no) 2001-11-15
US20020049153A1 (en) 2002-04-25
JP4115671B2 (ja) 2008-07-09
WO2000069911A1 (en) 2000-11-23
EA200100939A1 (ru) 2002-04-25
US6593295B2 (en) 2003-07-15
JP2009007371A (ja) 2009-01-15
ATE252601T1 (de) 2003-11-15
AU754770B2 (en) 2002-11-21
JP2006151986A (ja) 2006-06-15
JP2005255689A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
CN1191273C (zh) 长效促胰岛肽
US8093206B2 (en) Methods involving long lasting synthetic exendin-4 peptide conjugates
CN1351611A (zh) 病毒感染的长效融合肽抑制剂
CN1893980A (zh) 与白蛋白样物质相连的新glp－1类似物
CN1491233A (zh) 长效生长激素释放因子衍生物
CN1227567A (zh) Exendin类似物,其制备方法及含有它们的药物制剂
CN1293096C (zh) 合成甲状旁腺素类似物和甲状旁腺素相关肽的方法
CN1698881A (zh) 病毒感染的长效融合肽抑制剂
CN1929860A (zh) HIV gp41衍生肽的位点特异性化学修饰
CN1153784A (zh) 生物素衍生物
CN1918177A (zh) 新型glp－1化合物
HK1060137A (en) Long lasting growth hormone releasing factor derivatives
CN101048173A (zh) 延伸的胰高血糖素样肽－1类似物
CN101065133A (zh) 胰多肽家族基序及含有这些基序的多肽
HK1022701B (en) Exendin analogues, processes for their preparation and medicaments containing them
HK1022320B (en) New peptide compounds that are analogues of glucagon-like-peptide-1(7-37), a process for their preparation and pharmaceutical compositions containing them
HK1022320A1 (en) New peptide compounds that are analogues of glucagon-like-peptide-1(7-37), a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: KANGJIU CHEMICAL DEBIOTECH SA

Free format text: FORMER OWNER: CONJUCHEM, INC.

Effective date: 20060728

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20060728

Address after: Quebec

Patentee after: Conjuchem Biotechnologies Inc.

Address before: Quebec

Patentee before: Conjuchem, Inc.

ASS Succession or assignment of patent right

Owner name: KANGJIU CO., LTD.

Free format text: FORMER OWNER: CALIFORNIA CAPITAL EQUITY, LLC

Effective date: 20120316

Owner name: CALIFORNIA CAPITAL EQUITY, LLC

Free format text: FORMER OWNER: RSM RICHTER INC.

Effective date: 20120316

Owner name: RSM RICHTER INC.

Free format text: FORMER OWNER: CONJUCHEM INC.

Effective date: 20120316

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120316

Address after: California, USA

Patentee after: Kangjiu LLC

Address before: California, USA

Patentee before: ABRAXIS BIOSCIENCE, LLC

Effective date of registration: 20120316

Address after: California, USA

Patentee after: ABRAXIS BIOSCIENCE, LLC

Address before: Montreal, Quebec, Canada

Patentee before: RSM Leichete Co.

Effective date of registration: 20120316

Address after: Montreal, Quebec, Canada

Patentee after: RSM Leichete Co.

Address before: Montreal, Quebec, Canada

Patentee before: Conjuchem Biotechnologies Inc.

Effective date of registration: 20120316

Address after: Montreal, Quebec, Canada

Patentee after: Conjuchem Biotechnologies Inc.

Address before: Quebec

Patentee before: Conjuchem Biotechnologies Inc.

ASS Succession or assignment of patent right

Owner name: CHANGSHAN KAIJIEJIAN BIOLOGICAL MEDICINE RESEARCH

Free format text: FORMER OWNER: KANGJIU CO., LTD.

Effective date: 20130621

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: 050800 SHIJIAZHUANG, HEBEI PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20130621

Address after: 050800, Zhengding Road, Zhengding Town, Zhengding County, Hebei, Shijiazhuang province 9

Patentee after: Changshan kaijiejian biological drug R & D (Hebei) Co.,Ltd.

Address before: California, USA

Patentee before: Kangjiu LLC

CX01 Expiry of patent term

Granted publication date: 20050302

CX01 Expiry of patent term